2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3168

How Strong Cardiovascular Risk Factor Are Gouty Tophi?
Abstract Number: 1571

How Substantive Is Heart Rate Variability As a Predictor of Anti-TNF Treatment Outcome for Inflammatory Arthritis?
Abstract Number: 479

How to Recruit Anti-CCP Positive Patients from Primary Care
Abstract Number: 297

How Useful Is Magnetic Resonance Imaging (MRI) in Monitoring Patients with Myositis?
Abstract Number: 1208

How Well Do Acpas Discriminate and Predict RA in the General Population – a Study Based on 12,590 Population-Representative Swedish Twins
Abstract Number: 1766

HPV Vaccination of Nzbxw/F1 Mice
Abstract Number: 357

Human Parathyroid Hormone for Preventing and Treating Glucocorticoid-Induced Osteoporosis: Cochrane Systematic Review and Meta-Analysis
Abstract Number: 810

Human Parvovirus B19 Nonstructural Protein 1 (NS1) Helicase Breaks Tolerance to Self dsDNA: A Model for Viral Induction of Autoimmunity
Abstract Number: 199

Human Type 1 and Ncr-Negative Type 3 Innate Lymphoid Cells Accumulate in the Inflamed Synovium in Spondyloarthritis
Abstract Number: 310

Hyaluronic Acid Injections in Knee Osteoarthritis Patients Are Associated with Delay to Knee Arthroplasty
Abstract Number: 1815

Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence
Abstract Number: 1802

Hydroxychloroquine Level Variants and Predictors in a Connective Tissue Disease Population
Abstract Number: 1801

Hydroxychloroquine Retinopathy: Application of the 2011 Screening Guidelines in an Academic Practice
Abstract Number: 1806

Hydroxychloroquine Serum Levels and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis
Abstract Number: 3027

Hyperactivated State of Mucosal Associated Invariant T Cells Due to Activation Potency of Monocytes in Systemic Lupus Erythematous

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].